- Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
- Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
- Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
- Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
- Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
- Alto Neuroscience to Participate in Upcoming Investor Conferences
- Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
More ▼
Key statistics
On Friday, Alto Neuroscience Inc (ANRO:NYQ) closed at 13.49, 5.56% above its 52-week low of 12.78, set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.80 |
---|---|
High | 14.83 |
Low | 13.42 |
Bid | 13.40 |
Offer | 19.50 |
Previous close | 14.60 |
Average volume | 83.95k |
---|---|
Shares outstanding | 26.88m |
Free float | 23.36m |
P/E (TTM) | -- |
Market cap | 362.67m USD |
EPS (TTM) | -1.42 USD |
Data delayed at least 15 minutes, as of May 11 2024 00:00 BST.
More ▼